← back to the index
DV-005 cardiac electrophysiology 2005

The Guidant Ventak Prizm 2 DR — a Hidden Flaw, a Dead 21-Year-Old, a Guilty Plea

concealmentdeathelectrical-failuretherapy-failurecardiac-electrophysiologycardiology2000s2010s
Patients implanted
~109,000 ICDs under 2005 advisories/recalls (Prizm 2 DR + Contak Renewal)
Failure or harm
Internal arcing/short-circuit therapy failure; ≥7 deaths linked; 1 indexed (Oukrop, age 21)
In use
~3 yrs of concealment (Feb 2002 known → Jun 2005 recall)
Status
Recalled (Class I)

Summary

When Guidant Corporation issued its physician advisory on June 17, 2005 and the FDA classified it a Class I recall — the most serious category, reserved for defects with a reasonable probability of serious injury or death — the gap between the device's promise and its performance had already been measured in a single funeral. The Ventak Prizm 2 DR (Model 1861) was an implantable cardioverter-defibrillator, a machine whose entire purpose is to deliver a life-saving shock at the instant a patient's heart fibrillates. Guidant had known since February 2002 that a fraction of these units were prone to internal electrical arcing — a short-circuit across degraded insulation that could render the device inert exactly when it was called upon to fire. The company quietly re-engineered the device in November 2002 to fix the flaw, then told the FDA the change did not affect safety or effectiveness, and continued shipping the older, defect-prone inventory it had already built.

The concealed defect became a body on March 14, 2005, when Joshua Oukrop, a 21-year-old college student from Grand Rapids, Minnesota, with hypertrophic cardiomyopathy, collapsed and died on a mountain-biking trip in Utah. His implanted Prizm 2 DR had short-circuited and failed to shock him. His electrophysiologists, Dr. Robert Hauser and Dr. Barry Maron of the Minneapolis Heart Institute, asked Guidant what had happened; the company disclosed that it knew of the failure mode but had no plan to warn physicians. Hauser and Maron took the case to The New York Times, whose reporter Barry Meier published it on May 24, 2005. Public exposure, not the manufacturer's conscience, forced the recall three days later.

The reckoning was not regulatory but criminal. After a four-year investigation, the U.S. Department of Justice charged Guidant — by then a subsidiary of Boston Scientific, which had acquired it for roughly $27 billion in April 2006 — with making a materially false statement to the FDA about the Prizm 2 DR and failing to report a "correction" to its Contak Renewal defibrillators. Guidant pleaded guilty, and on January 12, 2011 U.S. District Judge Donovan W. Frank in St. Paul ordered it to pay more than $296 million in fines and forfeiture and serve three years of supervised probation — at the time the largest criminal penalty ever imposed for violating the Food, Drug, and Cosmetic Act. The episode became the foundational case for the principle that withholding a known device defect from regulators is not a paperwork lapse but a prosecutable crime.

Timeline

2000–2002
The Prizm 2 DR reaches patients
Guidant markets the Ventak Prizm 2 DR (Model 1861) ICD; tens of thousands are implanted into high-risk cardiac patients who depend on it to terminate lethal arrhythmias.
Feb 2002
The flaw is identified internally
Guidant becomes aware that the Prizm 2 DR is prone to internal electrical arcing — insulation degradation causing a short circuit that can disable the device's shocking function.
Nov 2002
Silent redesign
Guidant alters the Prizm's manufacturing to eliminate the arcing risk but tells the FDA the change does not affect safety or effectiveness; it keeps distributing previously built, defect-prone units.
2003–2004
Old inventory keeps shipping
Patients continue receiving the older, vulnerable Prizm 2 DR devices even though a corrected version exists; the failure mode is not disclosed to implanting physicians.
Mar 14, 2005
Joshua Oukrop dies
The 21-year-old Minnesota student collapses on a Utah bike trip when his Prizm 2 DR short-circuits and fails to deliver a shock.
Spring 2005
The doctors confront Guidant
Hauser and Maron of the Minneapolis Heart Institute learn from Guidant that the defect was known; the company indicates no plan to warn the field.
May 24, 2005
The New York Times breaks it
Reporter Barry Meier publishes the Oukrop case, exposing that Guidant had concealed the failure mode for roughly three years.
Jun 17 & 24, 2005
Advisories issued; Class I recall
Guidant sends physician communications on the Prizm 2 DR and Contak Renewal lines; the FDA classifies them as Class I recalls covering on the order of 109,000 ICDs.
Jul 21, 2005
NEJM publishes the autopsy of the affair
Robert Steinbrook's perspective in the New England Journal of Medicine details the concealment and frames the disclosure-vs.-alarm dilemma.
Apr 2006
Boston Scientific absorbs Guidant
Boston Scientific completes its ~$27 billion acquisition, inheriting the liability.
Nov 2010
Federal charges and guilty plea
After a four-year probe, the DOJ charges Guidant with a false statement (Prizm 2 DR) and failure to report a correction (Contak Renewal); Guidant pleads guilty.
Jan 12, 2011
Sentencing
Judge Donovan W. Frank imposes >$296 million in fines and forfeiture and three years' probation — the largest criminal penalty to date under the FD&C Act for a device maker.

A Machine Whose Only Job Was the Last Resort

The implantable cardioverter-defibrillator occupies a singular position in medicine: it is installed in people precisely because they are expected, someday, to suffer a sudden lethal arrhythmia, and its sole function is to detect that event and abort it with an internal shock. Patients who receive an ICD are by definition those for whom no other therapy is reliable. The Ventak Prizm 2 DR was such a device, implanted in tens of thousands of high-risk patients, including young people with inherited cardiac disease like Joshua Oukrop's hypertrophic cardiomyopathy. The design defect Guidant discovered in February 2002 attacked the one moment that justified the device's existence. A flaw in the internal insulation allowed electrical arcing — a short circuit — that could leave the unit unable to deliver its shock. For the overwhelming majority of patient-years the device sat silent and harmless; the hazard was invisible until the heart actually fibrillated. That property is what made concealment so seductive and so lethal: a defect that manifests only at the instant of crisis produces almost no everyday evidence, and a manufacturer can persuade itself the numbers are too small to disclose right up until the failure rate is written in obituaries.

The Fix Nobody Was Told About

Guidant did not ignore the defect; it corrected it — and that is the damning fact. In November 2002 the company changed the Prizm's manufacturing to eliminate the arcing risk, demonstrating that it both understood the mechanism and possessed the remedy. It then told the FDA the modification did not affect the device's safety or effectiveness, a characterization the government would later charge as a materially false statement, and it continued to distribute the older, uncorrected units already in its inventory. Physicians implanting a Prizm 2 DR in 2003 or 2004 had no way to know that a safer version of the same model existed or that the one in their hands carried a short-circuit risk the manufacturer had quietly engineered away. The asymmetry was total: Guidant held the failure data, the corrected design, and the supply chain, while the doctors and patients held only the marketing claim. The company's internal rationale echoed a recurring industry posture — that disclosing a low-frequency failure rate would needlessly alarm patients and prompt risky explant surgeries. But that judgment was made unilaterally, by the party with the financial stake, and withheld from the clinicians whose job it was to weigh exactly that trade-off for the individual in front of them.

The Body, the Newspaper, and the Indictment

The mechanism that finally moved the device was not surveillance but journalism. When Oukrop died in March 2005, Hauser and Maron — experienced electrophysiologists — pressed Guidant for an explanation and were told, in effect, that the failure mode was known and would not be broadcast. Convinced that physician silence had become complicity, they brought the case to The New York Times, whose May 24, 2005 report by Barry Meier converted a private grievance into a public scandal. Guidant issued its advisories within days, and the FDA escalated them to Class I recalls covering roughly 109,000 ICDs across the Prizm 2 DR and Contak Renewal lines, with at least seven deaths eventually linked to the malfunction. Civil settlements followed, but the durable verdict came from the Department of Justice. After a four-year investigation, prosecutors charged Guidant with lying to the FDA about the Prizm and failing to report a correction on the Contak Renewal; the company pleaded guilty, and on January 12, 2011 Judge Donovan W. Frank imposed more than $296 million in penalties and three years of probation. No regulator's routine audit caught the concealment; two doctors and a reporter did, and the criminal law did the rest.

Contributing Factors

01
A failure mode that hides until the crisis
The arcing defect produced no symptoms during ordinary operation and revealed itself only when the device was called to fire. Hazards that manifest exclusively at the moment of rescue generate almost no everyday signal, letting a manufacturer rationalize that the event rate is too low to disclose — the very property that makes such defects deadly when concealed.
02
A correction made and a notification withheld
Guidant redesigned the Prizm in November 2002 and told the FDA the change did not affect safety, while continuing to ship uncorrected stock. The existence of an in-hand fix is the most incriminating fact in any device case: it proves the maker understood both the mechanism and the remedy and chose not to warn.
03
Unilateral risk-benefit substitution
The company decided, on patients' behalf, that disclosure would do more harm than good by triggering needless explants. That clinical judgment belonged to the implanting physician and the patient, not to the party with a financial interest in silence; arrogating it converted a defensible medical trade-off into concealment.
04
Post-market surveillance that ran on luck
No regulatory system flagged the defect across three years; exposure depended on a single indexed death, two persistent doctors, and a newspaper. A safety regime that surfaces a known hazard only when a patient dies on the right day and the right clinician notices is not surveillance — it is hope.
05
Criminal liability as the only deterrent that bit
Civil settlements were absorbable costs of doing business; the difference was the DOJ's decision to prosecute non-reporting as a crime. Treating concealment of a known device defect as a felony-adjacent offense — not a paperwork fine — is what gave the obligation to report its first real teeth.

Aftermath

The material consequence was a then-record criminal penalty: more than $296 million in fines and forfeiture and three years' supervised probation, imposed on Guidant in January 2011 and borne by its parent, Boston Scientific. The durable ripple was regulatory and ethical. The Guidant affair, dissected in the New England Journal of Medicine and before the U.S. Senate Judiciary Committee, forced cardiology to confront how device-failure data is collected and disclosed; it accelerated independent device registries, sharpened FDA expectations for reporting design changes and corrections, and turned "the manufacturer knew" into a phrase prosecutors could build a case around. What remains is the precedent that a maker's silence about a known, life-critical defect is not a regulatory technicality but a prosecutable false statement — and that the people most likely to expose it are not auditors but the clinicians who watched a patient die. The Ventak Prizm 2 DR endures as the byword for concealment of a fatal device flaw: invoked whenever a manufacturer fixes a problem quietly, ships the old stock, and tells the regulator nothing changed.

Lessons

  1. When you discover a defect and engineer a fix, disclosure of the hazard becomes mandatory, not optional — the existence of your correction is proof you understood the danger, and a jury will read it that way.
  2. Never make the patient's risk-benefit decision for them by withholding a known failure rate; the choice to accept a low-probability defect or undergo explant belongs to the clinician and patient, who cannot weigh a hazard you have hidden.
  3. Treat "the event rate is too low to report" as a red flag in your own deliberations, because a failure mode that strikes only at the moment of rescue will always look statistically small until the deaths accumulate.
  4. Report design changes and corrections to the regulator truthfully, including those you believe are minor — a single materially false "no safety impact" statement is the thread on which a criminal case unravels.
  5. Build surveillance that does not depend on luck: if the only thing standing between a concealed defect and the public is one indexed death and one persistent doctor, assume the next defect will not be caught in time.

References